Allosteric ligands bind to receptors at sites that are distinct from those endogenous agonists and orthosteric pharmacological agents interact with. Both an allosteric and orthosteric ligand bind simultaneously to the receptor to form a ternary complex, where each ligand influences binding affinity of the other to the receptor, either positively or negatively. Allosteric modulators are an intensively studied group of receptor ligands because of their potentially greater selectivity over orthosteric ligands, with the possibility of fine tuning of the effects of endogenous neurotransmitters and hormones. The affinity of an unlabelled allosteric ligand is commonly estimated by measuring its effects on binding of a radio-labelled orthosteric tracer. This scenario is complicated by many folds when one studies the kinetics of interactions of two allosteric agents, added simultaneously, on binding of an orthosteric tracer. In this paper, we provide, for the first time, theoretical basis for analysis of such complex interactions. We have expanded our analysis to include the possibility of having two allosteric modulators interact with the same or different sites on the receptor. An added value of our analysis is to provide a tool to distinguish between the two situations. Finally, we also modelled binding of two molecules of one allosteric modulator to one receptor.

Department of Experimental and Clinical Pharmacology University of Minnesota College of Pharmacy Minneapolis MN United States of America

Department of Neurochemistry Institute of Physiology CAS Prague Czech Republic

Zobrazit více v PubMed

Leach K, Sexton PM, Christopoulos A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol Sci. 2007;28: 382–389. 10.1016/j.tips.2007.06.004 PubMed DOI

May LT, Leach K, Sexton PM, Christopoulos A. Allosteric Modulation of G Protein–Coupled Receptors. Annu Rev Pharmacol Toxicol. 2007;47: 1–51. 10.1146/annurev.pharmtox.47.120505.105159 PubMed DOI

Enrico Rovati G. Ligand-binding studies: Old beliefs and new strategies. Trends Pharmacol Sci. 1998;19: 365–369. 10.1016/S0165-6147(98)01242-5 PubMed DOI

Stoddart LA, White CW, Nguyen K, Hill SJ, Pfleger KDG. Fluorescence- and bioluminescence-based approaches to study GPCR ligand binding. Br J Pharmacol. 2016;173: 3028–3037. 10.1111/bph.13316 PubMed DOI PMC

Uddin R, Simms J, Poyner D. Functional characterisation of G protein-coupled receptors. Methods. Elsevier Inc.; 2018;147: 213–220. 10.1016/j.ymeth.2018.02.018 PubMed DOI

Lysíková M, Fuksová K, Elbert T, Jakubík J, Tuček S. Subtype-selective inhibition of [methyl- 3H]-N-methylscopolamine binding to muscarinic receptors by a-truxillic acid esters. Br J Pharmacol. 1999;127: 1240–1246. 10.1038/sj.bjp.0702646 PubMed DOI PMC

Tränkle C, Weyand O, Voigtländer U, Mynett A, Lazareno S, Birdsall NJM, et al. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors. Mol Pharmacol. 2003;64: 180–190. 10.1124/mol.64.1.180 PubMed DOI

Jakubík J, Zimčík P, Randáková A, Fuksová K, El-Fakahany EE, Doležal V. Molecular Mechanisms of Methoctramine Binding and Selectivity at Muscarinic Acetylcholine Receptors. Mol Pharmacol. 2014;86: 180–192. 10.1124/mol.114.093310 PubMed DOI

Doornbos MLJ, Pérez-Benito L, Tresadern G, Mulder-Krieger T, Biesmans I, Trabanco AA, et al. Molecular mechanism of positive allosteric modulation of the metabotropic glutamate receptor 2 by JNJ-46281222. Br J Pharmacol. 2016;173: 588–600. 10.1111/bph.13390 PubMed DOI PMC

Ehlert FJ. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol. 1988;33: 187–194. doi: 999 PubMed

Jakubík J, Bačáková L, El-Fakahany EE, Tuček S, Bacáková L, El-Fakahany EE, et al. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997;52: 172–179. 10.1124/mol.52.1.172 PubMed DOI

Hulme EC, Trevethick MA. Ligand binding assays at equilibrium: Validation and interpretation. Br J Pharmacol. 2010;161: 1219–1237. 10.1111/j.1476-5381.2009.00604.x PubMed DOI PMC

Jakubík J, El-Fakahany EE. Allosteric modulation of muscarinic receptors In: Myslivecek J, Jakubik J, editors. Muscarinic Receptor: From Structure to Animal Models. Springer Science + Business Media LLC, New York: Humana Press; 2016. pp. 95–130. Available: http://www.springer.com/gp/book/9781493928576

Lazareno S, Popham A, Birdsall NJM. Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors. Mol Pharmacol. 2002;62: 1492–1505. doi: 1759 PubMed

Lin DC-H, Guo Q, Luo J, Zhang J, Nguyen K, Chen M, et al. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol. 2012;82: 843–859. 10.1124/mol.112.079640 PubMed DOI PMC

Dror RO, Green HF, Valant C, Borhani DW, Valcourt JR, Pan AC, et al. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature. 2013;503: 295–299. 10.1038/nature12595 PubMed DOI

Noetzel MJ, Gregory KJ, Vinson PN, Manka JT, Stauffer SR, Lindsley CW, et al. A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol Pharmacol. 2013;83: 835–47. 10.1124/mol.112.082891 PubMed DOI PMC

Hill SJ, May LT, Kellam B, Woolard J. Allosteric interactions at adenosine A1 and A3 receptors: New insights into the role of small molecules and receptor dimerization. Br J Pharmacol. 2014;171: 1102–1113. 10.1111/bph.12345 PubMed DOI PMC

Sieghart W. Allosteric modulation of GABAAreceptors via multiple drug-binding sites [Internet]. 1st ed Advances in Pharmacology. Elsevier Inc.; 2015. 10.1016/bs.apha.2014.10.002 PubMed DOI

Hansen KB, Yi F, Perszyk RE, Furukawa H, Wollmuth LP, Gibb AJ, et al. Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol. 2018;150: 1081–1105. 10.1085/jgp.201812032 PubMed DOI PMC

Redka DS, Pisterzi LF, Wells JW. Binding of orthosteric ligands to the allosteric site of the M(2) muscarinic cholinergic receptor. Mol Pharmacol. 2008;74: 834–843. 10.1124/mol.108.048074 PubMed DOI

Guo D, Venhorst SN, Massink A, Van Veldhoven JPD, Vauquelin G, Ijzerman AP, et al. Molecular mechanism of allosteric modulation at GPCRs: Insight from a binding kinetics study at the human A1 adenosine receptor. Br J Pharmacol. 2014;171: 5295–5312. 10.1111/bph.12836 PubMed DOI PMC

The operational model of allosteric modulation of pharmacological agonism